TruAlt Bioenergy Reports Profit Surge and Strategic Divestment

Revenue grew to Rs 811.10 crore compared to Rs 114.86 crore last year, with profit reaching Rs 34.94 crore.

Reader Takeaway: Strong operational turnaround and revenue scaling, balanced by the need to successfully execute the upcoming Unit 5 sale.

What just happened

TruAlt Bioenergy released its unaudited financial results for the quarter and half-year ended September 30, 2026. The company successfully swung from a net loss of Rs 42.75 crore in Q2 FY26 to a consolidated profit of Rs 34.94 crore in Q2 FY27. Operations are clearly scaling, with total revenue for the quarter rising to Rs 811.10 crore. Alongside these robust financials, the board approved the sale of 'Unit 5' via a slump sale to Onkar Agro Sugars & Energy Private Limited for a consideration of Rs 171 crore.

Why this matters

The company’s return to profitability is driven by its core ethanol and compressed biogas segments. The decision to divest 'Unit 5' suggests management is actively streamlining its operations to optimize capital allocation. By classifying this unit as 'Assets Held for Sale,' the company is moving to reduce its asset footprint, likely to strengthen the balance sheet or reinvest in higher-margin opportunities.

Segment Performance

The company remains heavily invested in the ethanol sector, which generated Rs 1,418.12 crore in revenue for the half-year. Its newer segment, Compressed Biogas, contributed Rs 19.86 crore in revenue with a segment result of Rs 16.37 crore, highlighting the emerging importance of this division in the firm’s total portfolio.

What to track next

Investors should look for the finalization of the asset transfer agreement for 'Unit 5.' Specifically, shareholders should track how the company manages the Rs 35 crore capital advance previously tied to this unit and how the final proceeds from the sale are utilized to impact the overall debt-to-equity position of the firm.